Pfizer outsources PhIII Bosulif study to upstart Avillion

Avillion has scored one of its first risk-sharing deals on a late-stage pharma asset. The London-based Avillion Group struck a deal to do a Phase III study of Pfizer's ($PFE) Bosulif (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia. The drug is already approved as a second-line leukemia therapy. Clarus Ventures and Abingworth launched Avillion about a year ago, following a pioneering business model laid out by SFJ Pharma in Asia. The group is run by an experienced CRO team which takes on the cost of $50 million to $100 million late-stage studies in exchange for a piece of the action or some other payout. In this instance, Pfizer retains commercialization rights but will pay out milestones based on the success of the program. Release

Suggested Articles

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.

Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.

The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.